Attorney AdvertisingBronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request ...

Attorney AdvertisingBronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Ebang International Holdings (NASDAQ: EBON)
Class Period: June 26, 2020 - April 5, 2021
Deadline: June 7, 2021
For more info: www.bgandg.com/ebon
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the proceeds from Ebang's public offerings had been directed to an low yield, long term bonds to an underwriter and to related parties rather than used to develop the Company's operations; (2) Ebang's sales were declining and the Company had inflated reported sales, including through the sale of defective units; (3) Ebang's attempts to go public in Hong Kong had failed due to allegations of embezzling investor funds and inflated sales figures; (4) Ebang's purported cryptocurrency exchange was merely the purchase of an out-of-the-box crypto exchange; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Amdocs Limited (NASDAQ: DOX)
Class Period: December 13, 2016 - March 30, 2021,
Deadline: June 8, 2021
For more info: www.bgandg.com/dox
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (2) Amdocs concealed its large borrowing; (3) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

Champignon Brands Inc. (OTC: SHRMF)
Class Period: March 27, 2020 - February 17, 2021
Deadline: June 9, 2021
For more info: www.bgandg.com/shrmf
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) Champignon had undisclosed material weaknesses and insufficient financial controls; (2) Champignon's previously issued financial statements were false and unreliable; (3) Champignon's earlier reported financial statements would need to be restated; (4) Champignon's acquisitions involved an undisclosed related party; (5) as a result of the foregoing and subsequent reporting delays and issues, the British Columbia Securities Commission would suspend Champignon's from trading; and (6) as a result, defendants' statements about Champignon's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch Investor Series today announced their agenda is updated for the Virtual Investor Luncheon on Tuesday November 30. Individual investors, finance professionals, and analysts are invited to register now to attend the Luncheon.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

Keep reading... Show less

What Does the FDA Think About Psychedelics?

The development of the psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading authority for drug approvals in the US. This federal body determines whether medical products will ultimately reach the hands of patients.

The FDA reviews the clinical data created by established medical studies evaluating the feasibility of drug compounds or products as treatments for specific ailments.

Keep reading... Show less

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (License Agreement), whereby it acquired a worldwide license (excluding China Taiwan Macau and Hong Kong ) from iX Biopharma Ltd (iX Biopharma) for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™.

Keep reading... Show less

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the "Closing Shares") to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos. Seelos will receive $20.0 million in gross proceeds.

Keep reading... Show less

Hollister Biosciences Inc. Announces Results of Its 2021 Annual General and Special Shareholder Meeting

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company " or " Hollister Biosciences ") today announced results of its 2021 Annual General and Special Shareholder Meeting (the " Meeting ") held on November 22, 2021 .

Keep reading... Show less

COMPASS Pathways granted fifth US patent for crystalline psilocybin

London, UK - 23 November 2021

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS's 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong.

Keep reading... Show less

Top News

Related News